OPKO Health Expands Collaboration Agreement with Entera Bio
OPKO Health (OPK), through its wholly owned subsidiary, OPKO Biologics, and Entera Bio (ENTX), announced the expansion of their 2025 Collaboration and License Agreement to advance the first oral long-acting PTH analog as a once-daily tablet for patients with hypoparathyroidism. The additional program combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab technology. Following favorable pharmacodynamic and pharmacokinetic data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an IND application with the U.S. Food and Drug Administration in late 2026. Under the expanded collaboration agreement, OPKO and Entera will each hold a 50% pro-rata ownership interest in the LA-PTH hypoparathyroidism program and will each be responsible for 50% of the program's development costs. The companies maintain their previously announced 60%/40% ownership structure and cost-sharing arrangement for the oral OXM program for metabolic and fibrotic disorders.
Trade with 70% Backtested Accuracy
Analyst Views on OPK
About OPK
About the author
OPKO Health to Participate in 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: OPKO Health will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, where management will engage in one-on-one meetings with investors, showcasing the company's strategic positioning in the biopharmaceutical and diagnostics sectors.
- Live Webcast: On January 14 at 1:30 p.m. Pacific Time, management will participate in a fireside chat that will be webcast live, allowing investors to gain real-time insights into the company's latest developments and future directions.
- Investor Relations Enhancement: By facilitating direct communication with investors, OPKO Health aims to strengthen its market engagement, enhance its visibility in the biopharmaceutical industry, and further drive its market expansion efforts.
- Industry Positioning: OPKO Health is committed to establishing industry-leading positions in rapidly growing markets by leveraging its expertise in discovery, development, and commercialization, thereby demonstrating its innovative capabilities in the biopharmaceutical and diagnostics fields.
Reasons to Keep OPKO Health Stock in Your Portfolio at This Time
Growth Potential: OPKO Health, Inc. is positioned for growth, particularly due to its leading product RAYALDEE, which has shown solid sales momentum, although the company faces challenges from competition and reliance on this single product.
Financial Performance: The company's shares have declined 10.2% this year, contrasting with industry gains, and it anticipates a 30% growth for fiscal 2026, despite recent earnings misses and a projected revenue decline for Q4 2025.
Strategic Partnerships: OPKO has engaged in several strategic collaborations, including agreements with Regeneron Pharmaceuticals and Entera Bio, aimed at enhancing its product offerings and operational efficiency.
Clinical Trials and Innovations: The company is advancing in clinical trials, including a Phase 1/2a trial for a new oncology treatment and ongoing development of an Epstein-Barr Virus vaccine, indicating a commitment to innovation in its therapeutic pipeline.
Insider Buying Update for Friday, November 21: GLOO, OPK
GLOO Insider Purchase: Patrick P. Gelsinger bought 125,000 shares of GLOO at $8.00 each, totaling $1M, and is currently up 17.6% based on a trading high of $9.41.
OPKO Health Insider Purchase: CEO Phillip Frost purchased $759,115 worth of OPKO Health, acquiring 580,000 shares at $1.31 each, marking his 18th purchase in the past year, totaling $6.27M at an average of $1.45 per share.
Market Performance: GLOO's stock is up about 2.2% on Friday, while OPKO Health is trading up approximately 2.3% on the same day.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
NextPlat Reports Third Quarter 2025 Results
Financial Performance: NextPlat Corp reported Q3 2025 revenue of approximately $13.8 million, a decrease from $15.4 million in Q3 2024, primarily due to a decline in healthcare operations. However, the company anticipates improved performance in Q4 2025 driven by increased prescription volumes and cost-cutting measures.
Cost-Cutting Initiatives: The company has successfully reduced operating expenses to approximately $4.7 million in Q3 2025, down from $7.8 million in the previous year, through staff reductions and operational efficiencies, which are expected to contribute to further improvements in financial metrics.
Healthcare Segment Growth: NextPlat's healthcare segment is experiencing a resurgence with increased prescription volumes, particularly in the 340B program, and the addition of new customers, which is expected to drive significant revenue growth in the upcoming quarters.
E-Commerce Developments: The e-commerce division continues to perform well, particularly in satellite-based connectivity and IoT products, with ongoing expansion in sales channels and new product launches, including a marketing campaign for Florida Sunshine products in China.
Jefferies Lowers OPKO Health Rating to Hold and Reduces Price Target to $1.6
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
OPKO Health (OPK) Q3 Earnings Review: Analyzing Key Metrics Against Estimates
OPKO Health Financial Performance: For Q3 2025, OPKO Health reported a revenue of $151.7 million, a 12.6% decrease from the previous year, with an EPS of $0.03, matching last year's figure.
Earnings Surprise: The company's revenue fell short of the Zacks Consensus Estimate of $157.11 million, resulting in a -3.44% surprise, while it achieved a +250% EPS surprise against a consensus estimate of -$0.02.
Investor Insights: Investors are advised to focus on key metrics that provide deeper insights into OPKO's performance, beyond just headline revenue and earnings figures.
Market Trends: The demand for data is driving growth in the semiconductor market, with emerging companies poised to benefit from this trend, particularly those producing hardware not made by larger firms like NVIDIA.
OPKO Health to Participate in 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: OPKO Health will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, where management will engage in one-on-one meetings with investors, showcasing the company's strategic positioning in the biopharmaceutical and diagnostics sectors.
- Live Webcast: On January 14 at 1:30 p.m. Pacific Time, management will participate in a fireside chat that will be webcast live, allowing investors to gain real-time insights into the company's latest developments and future directions.
- Investor Relations Enhancement: By facilitating direct communication with investors, OPKO Health aims to strengthen its market engagement, enhance its visibility in the biopharmaceutical industry, and further drive its market expansion efforts.
- Industry Positioning: OPKO Health is committed to establishing industry-leading positions in rapidly growing markets by leveraging its expertise in discovery, development, and commercialization, thereby demonstrating its innovative capabilities in the biopharmaceutical and diagnostics fields.
Reasons to Keep OPKO Health Stock in Your Portfolio at This Time
Growth Potential: OPKO Health, Inc. is positioned for growth, particularly due to its leading product RAYALDEE, which has shown solid sales momentum, although the company faces challenges from competition and reliance on this single product.
Financial Performance: The company's shares have declined 10.2% this year, contrasting with industry gains, and it anticipates a 30% growth for fiscal 2026, despite recent earnings misses and a projected revenue decline for Q4 2025.
Strategic Partnerships: OPKO has engaged in several strategic collaborations, including agreements with Regeneron Pharmaceuticals and Entera Bio, aimed at enhancing its product offerings and operational efficiency.
Clinical Trials and Innovations: The company is advancing in clinical trials, including a Phase 1/2a trial for a new oncology treatment and ongoing development of an Epstein-Barr Virus vaccine, indicating a commitment to innovation in its therapeutic pipeline.
Insider Buying Update for Friday, November 21: GLOO, OPK
GLOO Insider Purchase: Patrick P. Gelsinger bought 125,000 shares of GLOO at $8.00 each, totaling $1M, and is currently up 17.6% based on a trading high of $9.41.
OPKO Health Insider Purchase: CEO Phillip Frost purchased $759,115 worth of OPKO Health, acquiring 580,000 shares at $1.31 each, marking his 18th purchase in the past year, totaling $6.27M at an average of $1.45 per share.
Market Performance: GLOO's stock is up about 2.2% on Friday, while OPKO Health is trading up approximately 2.3% on the same day.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
NextPlat Reports Third Quarter 2025 Results
Financial Performance: NextPlat Corp reported Q3 2025 revenue of approximately $13.8 million, a decrease from $15.4 million in Q3 2024, primarily due to a decline in healthcare operations. However, the company anticipates improved performance in Q4 2025 driven by increased prescription volumes and cost-cutting measures.
Cost-Cutting Initiatives: The company has successfully reduced operating expenses to approximately $4.7 million in Q3 2025, down from $7.8 million in the previous year, through staff reductions and operational efficiencies, which are expected to contribute to further improvements in financial metrics.
Healthcare Segment Growth: NextPlat's healthcare segment is experiencing a resurgence with increased prescription volumes, particularly in the 340B program, and the addition of new customers, which is expected to drive significant revenue growth in the upcoming quarters.
E-Commerce Developments: The e-commerce division continues to perform well, particularly in satellite-based connectivity and IoT products, with ongoing expansion in sales channels and new product launches, including a marketing campaign for Florida Sunshine products in China.
Jefferies Lowers OPKO Health Rating to Hold and Reduces Price Target to $1.6
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
OPKO Health (OPK) Q3 Earnings Review: Analyzing Key Metrics Against Estimates
OPKO Health Financial Performance: For Q3 2025, OPKO Health reported a revenue of $151.7 million, a 12.6% decrease from the previous year, with an EPS of $0.03, matching last year's figure.
Earnings Surprise: The company's revenue fell short of the Zacks Consensus Estimate of $157.11 million, resulting in a -3.44% surprise, while it achieved a +250% EPS surprise against a consensus estimate of -$0.02.
Investor Insights: Investors are advised to focus on key metrics that provide deeper insights into OPKO's performance, beyond just headline revenue and earnings figures.
Market Trends: The demand for data is driving growth in the semiconductor market, with emerging companies poised to benefit from this trend, particularly those producing hardware not made by larger firms like NVIDIA.
